human
The task is to decide the Hallmarks of Cancer (HOC) taxonomy of the article based on its abstract. The input is an abstract text. There are 10 topics you will need to decide whether the article is related to. Topics: sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, genomic instability and mutation, tumor promoting inflammation, cellular energetics, avoiding immune destruction. The output should be topics from the above 10 topics, that are related to the input article. Please note one article can be related to multiple topics. Output format: provide a semicolon-separated list of relevant topics.
    ###
    INPUT: HM781-36B is an orally administered pan-human epidermal growth factor receptor ( HER ) inhibitor . To explore the role of pan-HER inhibitor in breast cancer , we investigated the antitumor effect and mechanisms of HM781-36B in breast cancer cell lines . Six breast cancer cell lines ( BT474 , MDA-MB-453 , SK-BR-3 , T47D , MCF-7 , and MDA-MB-231 ) were tested . The growth inhibitory effect was assessed using the tetrazolium bromide [ 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl-tetrazolium bromide ] assay . The cell cycle at various concentrations of HM781-36B was analyzed by flow cytometry , and analysis of downstream molecules was performed by western blot analysis . Interaction of HM781-36B with cytotoxic chemotherapeutic agents was analyzed by combination index using CalcuSyn . The HER2-amplified cells ( SK-BR-3 , BT474 , and MDA-MB-453 ) were sensitive to HM781-36B ( IC50=0.001 Î¼mol/l , 0.0012 Î¼mol/l , and 0.0095 Î¼mol/l , respectively ) . HM781-36B induced G1 arrest and resulted in apoptosis . It reduced the level of p-HER2 , p-AKT , p-ERK , and p-STAT3 . HM781-36B combined with 5-fluorouracil , cisplatin , paclitaxel , or gemcitabine showed a synergistic inhibitory effect on the HER2-amplified and on some of the HER2-nonamplified breast cancer cells . HM781-36B could be a promising treatment for HER2-amplified breast cancer as a single agent or in combination with cytotoxic agents and can be a candidate for treatment of HER2-nonamplified breast cancer in combination with cytotoxic agents .
    OUTPUT:

agent
resisting cell death;sustaining proliferative signaling
The task is to decide the Hallmarks of Cancer (HOC) taxonomy of the article based on its abstract. The input is an abstract text. There are 10 topics you will need to decide whether the article is related to. Topics: sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, genomic instability and mutation, tumor promoting inflammation, cellular energetics, avoiding immune destruction. The output should be topics from the above 10 topics, that are related to the input article. Please note one article can be related to multiple topics. Output format: provide a semicolon-separated list of relevant topics.
    ###
    INPUT: HM781-36B is an orally administered pan-human epidermal growth factor receptor ( HER ) inhibitor . To explore the role of pan-HER inhibitor in breast cancer , we investigated the antitumor effect and mechanisms of HM781-36B in breast cancer cell lines . Six breast cancer cell lines ( BT474 , MDA-MB-453 , SK-BR-3 , T47D , MCF-7 , and MDA-MB-231 ) were tested . The growth inhibitory effect was assessed using the tetrazolium bromide [ 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl-tetrazolium bromide ] assay . The cell cycle at various concentrations of HM781-36B was analyzed by flow cytometry , and analysis of downstream molecules was performed by western blot analysis . Interaction of HM781-36B with cytotoxic chemotherapeutic agents was analyzed by combination index using CalcuSyn . The HER2-amplified cells ( SK-BR-3 , BT474 , and MDA-MB-453 ) were sensitive to HM781-36B ( IC50=0.001 Î¼mol/l , 0.0012 Î¼mol/l , and 0.0095 Î¼mol/l , respectively ) . HM781-36B induced G1 arrest and resulted in apoptosis . It reduced the level of p-HER2 , p-AKT , p-ERK , and p-STAT3 . HM781-36B combined with 5-fluorouracil , cisplatin , paclitaxel , or gemcitabine showed a synergistic inhibitory effect on the HER2-amplified and on some of the HER2-nonamplified breast cancer cells . HM781-36B could be a promising treatment for HER2-amplified breast cancer as a single agent or in combination with cytotoxic agents and can be a candidate for treatment of HER2-nonamplified breast cancer in combination with cytotoxic agents .
    OUTPUT:
